Abstract
Liver metastases are present on initial diagnosis of large bowel cancer in 25%–30% of patients [1]. After curative resection of colorectal primary tumors, the liver again is the most frequent site of relapse [2, 3]. Once liver metastases have developed the prognosis is poor, with an expected median survival time of 6–9 months [1,4], the extent of the tumor being the most important prognostic factor [5]. A great deal of work has been done to determine the factors that influence development of liver metastases. There is evidence that tumor cells embolize into the portal venous system via the mesenteric veins and enter the liver. In 1957, Dukes [6] found evidence of venous spread in 17% of operative rectal cancer specimens. Fisher and Turnbull [7] discovered tumor cells in the mesenteric venous blood of 32% in colorectal carcinoma patients at surgery. Suggesting that manipulation of the tumor may force malignant cells into the circulation, they initiated the so-called no-touch isolation technique [8]. However, not all circulating cancer cells give rise to metastases. Several reports have shown that patients with malignant cells in the portal venous blood fare no worse than those without [9, 10].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bengmark S, Hafström L (1969) The natural history of primary and secondary malignant tumours of the liver. 1. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23:198–202
Cedermark BJ, Schultz SS, Bakshi S, Parthasarathy KL, Mittelman A., Evans TJ (1977) Value of liver scan in the follow-up study of patients with adenocarcinoma of the colon and rectum. Surg Gynec Obstet 144:745–748
Weiss L, Grundmann E, Torhost J, Hartweit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CHW, Lopez MJ, Shaw-Dunn RI, Sugar J, Davies JD, Day DW, Harlos JP (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195–203
Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dockerty MB (1964) The natural history of carcinoma of the colon and rectum. Am J Surg 108:826–829
Wanebo H (1984) A staging system for liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 3:143, C-560
Dukes CE (1957) Discussion on major surgery in carcinoma of the rectum, with or without colostomy, excluding the anal canal and including the rectosigmoid. Proc R Soc Med 50:1031–1052
Fisher ER, Turnbull RB (1955) The cytological demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal cancer. Surg Gynecol Obstet 100:102–106
Turnbull RB (1970) Cancer of the colon: 5-10 years’ survival rates following resection utilizing the isolation technique. Ann R Coll Surg Engl 46:243–250
Roberts S, Jonasson O, Long L, McGrath R, McGrew EA, Cole WH (1961) Clinical significance of cancer cells in the circulating blood: two-to five-year survivals. Ann Surg 154:362–371
Seilwood RA, Kuper SW, Burn JI, Wallace EN (1965) Circulating cancer cells: the influence of surgical operations. Br J Surg 52:69–72
De Vita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. The James Ewing lecture. Cancer 51:1209–1220
Schabel FM (1975) Concepts for systemic treatment of micrometastases. Cancer 35:15–24
Metzger U, Schneider K, Largiadèr F (1982) Adjuvant therapy of colorectal cancer, an overview. Oncology 5:228–236
Higgins GA, Amadeo JH, McElhinney J, McCaughan JJ, Keehn RJ (1984) Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 53:1–8
Lawrence W, Terz JJ, Horsley S, Donaldson M, Lovett WL, Brown PW, Ruffner BW, Regelson W (1975) Chemotherapy as an adjuvant to surgery for colorectal cancer. Ann Surg 181:616–623
Holyoke ED, Moertel CG, O’Connell MJ and the Gastrointestinal Tumor Study Group (1984) Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 310:737–743
Ackermann NB (1974) The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75:589–596
Taylor I, Bennett R, Sherriff S (1979) The blood supply of colorectal liver metastases. Br J Cancer 39:749–756
Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM (1987) Perfusion of colorectal hepatic metastases. Cancer 59:1547–1553
Almersjö O, Brandberg A, Gustavsson B (1975) Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man. Cancer Lett 1:113–118
Speyer JL, Sugarbaker PH, Collins, JM (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922
Berger MR, Henne TH, Aguiar JLA, Bartkowski R, Dörsam J, Geelhaar GH, Schlag P, Herfarth C, Schmähl D (1986) Experiments on the toxicity of locoregional liver chemotherapy with 5-fluoro-2′-deoxyuridine and 5-fluorouracil in an animal model. Recent Results Cancer Res 100:148–156
Laufman LR, Nims TA, Guy JT, Guy JF, Courter S (1984) Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer. J Clin Oncol 2:1382–1389
Taylor I (1978) Cytotoxic perfusion for colorectal liver metastases. Br J Surg 65:109 114
Petrelli NJ, Bracewiecz PA, Evans JT, Ledesma EJ, Lawrence DD, Mittelman A (1984) Hepatic artery ligation for liver metastasis in colorectal carcinoma. Cancer 53:1347–1353
Morales F, Bell M, McDonald GD, Cole WH (1957) The prophylactic treatment of cancer at the time of operation. Ann Surg 146:588–595
Burchenal JH (1976) Adjuvant therapy — theory, practice, and potential. The James Ewing lecture. Cancer 37:46–57
Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488–1492
Taylor L, Rowling JT, West C (1979) Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 66:833–837
Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C (1985) A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72:359–363
Metzger U, Mermillod B, Aeberhard P, Gloor F, Bissat A, Egeli R, Laffer U et al (1987) Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality. World J Surg 11:452–458
Bassermann R (1986) Changes of vascular pattern of tumors and surrounding tissue during different phases of metastatic growth. Recent Results Cancer Res 100:256–267
Daly JM, Kemeny N, Sigurdson E, Oderman P, Thorn A (1987) Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg 122:1273–1277
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Metzger, U., Laffer, U. (1990). Intraportal Chemotherapy for Colorectal Hepatic Metastases. In: Jakesz, R., Rainer, H. (eds) Progress in Regional Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74818-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-74818-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74820-2
Online ISBN: 978-3-642-74818-9
eBook Packages: Springer Book Archive